Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Managing high-risk/MRD positive and standard-risk/MRD myeloma

Myeloma Knowledge Exchange 2021 (MyKE Myeloma)

Published: 29 Oct 2021

Views: 786

Rating:

Save

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

Dr Stefania Oliva speaks to ecancer about managing high-risk/MRD positive and standard-risk/MRD myeloma. Initially, she talks about the treatment risks for patients with newly diagnosed multiple myeloma versus high-risk myeloma patients.

She mentions several risk factors for myeloma patients. Dr Oliva says ESMO guidelines can be used to help make clinical decisions, particularly for transplant-ineligible patients. She further discusses the role of MRD in decision making.

Dr Oliva mentions some trials regarding the treatment of high-risk and low-risk patients. She concludes, by saying that for high-risk settings more trials are required to find a better low-risk treatment.

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

Encouraging results using mismatched unrelated donors in stem cell transplantation

Dr Monzr Al Malki and Dr Steven Devine

Encouraging results using mismatched unrelated donors in stem cell transplantation ( Dr Monzr Al Malki and Dr Steven Devine )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Hodgkin’s and non-Hodgkin’s lymphomas (NHL)

Dr Jose Sandoval Sus - Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Florida, USA

Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ( Dr Jose Sandoval Sus - Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Florida, USA )

More from ecancer